MEI Pharma (MEIP) 8-K These slides and the accompanying oral presentation contain

[ NASDAQ: MEIP ]

Analyst & Investor Event

December 8, 2014

Exhibit 99.1

2

Forward-Looking Statements

These slides and the accompanying oral presentation contain

forward-looking statements. Actual events or results may differ

materially from those projected in any of such statements.

Additional information concerning factors that may cause actual

events or results to differ from those projected is contained in

MEI

Pharma’s most recent annual report on Form 10-K and quarterly

reports on Form 10-Q, as well as other subsequent filings with the

SEC.

3

Agenda

Time

Presentation

Speaker

6:00 pm

Welcome & Introduction

Daniel P. Gold, PhD

6:05 pm

Pracinostat: A Differentiated HDAC Inhibitor

Guillermo Garcia-Manero, MD

Update on MDS Pilot Study

Guillermo Garcia-Manero, MD

Review of Front Line AML Data

Guillermo Garcia-Manero, MD

6:25 pm

Next Steps for Pracinostat in AML

Robert D. Mass, MD

Preview of Front Line MDS Data

Robert D. Mass, MD

6:30 pm

Q & A

All

7:00 pm

Conclusion

4

Introductions

Guillermo Garcia-Manero, MD

Professor, Department of Leukemia, MD Anderson Cancer Center

Chief, Section of Myelodysplastic Syndromes, MD Anderson Cancer

Center

Robert D. Mass, MD

Professor, Department of Leukemia, MD Anderson Cancer Center

Chief, Section of Myelodysplastic Syndromes, MD Anderson Cancer

Center

Deputy Chair, Translational Research, MD Anderson Cancer Center

Co-Chair, MDS Clinical Research Consortium

Principal Investigator of Pracinostat studies

Chief Medical Officer, MEI Pharma

Former Head of Medical Affairs, BioOncology, Genentech

Clinical Development Pipeline

5

Pracinostat

HDAC Inhibitor

Myelodysplastic

Syndrome

Front Line, Int-2 & High-Risk

Azacitidine

(Vidaza

®

)

Acute Myeloid Leukemia

Front Line, Elderly

Azacitidine

(Vidaza

®

)

Myelodysplastic

Syndrome

Refractory to HMA

Azacitidine

(Vidaza

®

) or

Decitabine

(Dacogen

®

)

Myelofibrosis

Front Line &

Relapsed/Refractory

Ruxolitinib

(Jakafi

®

)

ME-344

Mitochondrial

Inhibitor

Small Cell Lung Cancer

Advanced or Metastatic

Topotecan

(Hycamtin

®

)

Ovarian

Cancer

Advanced or Metastatic

Topotecan

(Hycamtin

®

)

PWT143

PI3K Delta Inhibitor

Hematologic Cancers

DRUG CANDIDATE

INDICATION / COMBINATION

PHASE I

PRE-CLINICAL

PHASE II

PHASE III

Pracinostat: A Clinical Perspective

Guillermo Garcia-Manero, MD

MD Anderson Cancer Center

7

Pracinostat: A Differentiated HDAC Inhibitor

•

Potent inhibitor of Class I, II and IV HDAC isoenzymes

•

Tested in 300+ patients in multiple Phase I and Phase II clinic trials

Hematologic and solid tumor indications, adult and pediatric patients

Well tolerated

Manageable side effects consistent with drugs of this class

•

Best-in-class pharmacokinetic profile, broadly active

SB991, the major in vivo metabolite of Pracinostat, demonstrates higher

activity than Pracinostat

Combined on target IC

50

activity for HDAC1 predicted to be >24 hours

8

Evidence of Clinical Activity in MDS and AML

•

Evidence

of

single-agent

activity

in

elderly

AML

1

14% (2/14) CR rate in Phase I dose-escalation study

•

Evidence

of

activity

in

combination

with

azacitidine

in

MDS

2

80% (8/10) CR/CRi rate in pilot Phase II study

Rapid complete bone marrow responses observed

•

50% (5/10) achieved complete cytogenetic bone marrow response

•

50% (5/10) went on to bone marrow transplantation

Quintás-Cardama et al. Very high rates of clinical and cytogenetic response with the

combination of the histone deacetylase inhibitor Pracinostat (sb939) and 5-azacitidine in

high-risk myelodysplastic syndrome. 2012 ASH Annual Meeting, Abstract 3821

1

2

G.

Garcia-Manero,

et

al.

Phase

1

Study

of

the

Oral

Deacetylase

Inhibitor,

SB939,

in

Patients

with

Advanced

Hematologic

Malignancies.

2010

ASH

Annual

Meeting,

Abstract

3292

9

MDS Pilot Study –

Patient Characteristics

Patient

1

2

3

4

5

6

7

8

9

10

Median (range)

Age (years)

71

71

63

57

22

70

18

71

52

66

64.5 (18-71)

Sex

F

M

F

F

F

M

M

F

F

F

% BM blasts

18

8

2

9

3

3

6

1

12

9

7 (1-18)

Hemoglobin g/dL

11

9.3

10.9

9.5

10.2

9.2

8.2

10.7

11.1

9.9

10.05 (8.2-11.1)

WBC K/uL

3.2

1.5

2.3

2.5

0.7

2.6

9.3

4.5

1.2

1.5

2.4 (0.7-9.3)

ANC K/uL

1.44

0.2

1.3

1.55

0.9

1.7

4.7

2.8

0.4

0.25

1.37 (0.2-4.7)

Platelets k/uL

29

56

130

14

27

32

269

13

92

52

42 (13-269)

Creatinine mg/dL

1.03

0.99

0.72

0.7

0.5

1

0.8

0.67

0.78

0.6

0.75 (0.5-1.03)

Bilirubin mg/dL

1.1

0.7

0.6

1.3

0.4

1

1.1

0.6

0.8

0.5

0.75 (0.4-1.3)

Cytogenetics

C

C

C

-7

-7

C

t(6;9)

-7

C

C

t-MDS

Y

Y

Y

Y

N

Y

Y

Y

Y

N

Response

CR

CRp

CR

CRp

CR

NR

CRp

CR

CR

CR

MDS Pilot Study…

Three Years Later

10

11

Stage 2 (n = 13)

Pracinostat plus Azacitidine

Three or more patients required to achieve CR/CRi/MLFS to advance to Stage 2

Stage 1 (n = 27)

Pracinostat plus Azacitidine

Elderly (Age

65 years) Patients with Newly Diagnosed AML

AML, acute myeloid leukemia; CR, complete response; CRi, complete response with incomplete blood count recovery; MLFS, morphologic leukemia-free state

Phase II Study in Front Line AML (MEI-004)

12

•

Pracinostat 60 mg is administered orally 3 days a week (days 1,3

and 5 of

each week) for 21 days of each 28 day cycle

•

Azacitidine is administered subcutaneously or intravenously on days 1-7 or

days 1-5 & 8-9 (per site preference) of each 28-day cycle

•

Dose Modifications:

Reductions

Treatment Regimen

•

Indicated for treatment related

Grade 3 non-hematologic toxicity following

maximal medical treatment

•

Indicated for treatment related

Grade 3 hematologic toxicity in the absence

of disease

Delays (between or within cycles)

•

Subsequent reduction to 45 mg of Pracinostat is allowed

•

Begin with Azacitidine which may be reduced to 75% of the starting dose

13

•

Key Inclusion:

Age

65 years

Newly diagnosed de novo, secondary, or treatment-related AML with

intermediate or unfavorable-risk cytogenetics based on the Southwest Oncology

Group (SWOG) classifications (Slovak et al, 2000).

20% bone marrow blasts

Adequate renal, cardiac and liver function

QTcF <450 ms for males or <470 ms for females

•

Key Exclusion:

–

Acute promyelocytic leukemia (FAB M3);  t(15;17), t(8;21), t(16;16), del(16q), or

inv(16) karyotype

–

Candidate for intensive chemotherapy (induction chemotherapy, bone marrow, or

stem cell transplant) within the next 4 months

–

Active central nervous system (CNS) disease

Eligibility Criteria

14

Study Evaluations

•

Primary Endpoint: Complete Response (CR) + Complete Response with

Incomplete Blood Count Recovery (CRi) + Marrow CR (Morphologic

Leukemia Free State, MLFS)

•

Secondary Endpoints:

Overall response rate (CR + CRi + partial response [PR] + PR with incomplete

blood count recovery [PRi] + MLFS)

Complete cytogenetic response (CRc) + molecular complete remission (CRm)

Duration of response

Event free survival (EFS)

Overall survival (OS)

Assess the tolerability and adverse event profile

•

Response assessments end of cycle 1 or 2, and then every other cycle until

CR is achieved or as clinically indicated

15

N = 41

Number of Patients Active

25

Number of Patients Discontinued

Reasons

for

discontinuation:

Progressive

Disease

Adverse Event

Other 

16

6

6

4

50 patients enrolled between December 2013 –

December 2014 at 15 sites

41 patients enrolled at data cutoff

Other –

includes patient or physician decision

Patient Disposition

16

Number of Patients at Baseline

n = 41 (%)

Age (years)

Median

76

Range

69 -

84

Gender

Male

24 (59)

Female

17 (41)

Newly diagnosed de novo

29 (71)

Secondary (AHD & treatment related)

12  (29)

0-1

33 (80)

2

8 (20)

Median

38

20-29% Range

13 (32)

30-50% Range

15 (36)

>50% Range

13 (32)

Intermediate

23 (56)

High

17 (41)

Not Evaluable

1 (3)

AHD, antecedent hematologic disorder; AML, acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group

AML Disease Status

ECOG Status

Bone Marrow Blasts at Baseline

Cytogenetic Risk Category

Baseline Characteristics

17

Treatment Emergent Adverse Events in

10%

of Patients (all causality)

All Grades (%), n=41

Grades 3-4 (%), n=41

Hematologic

Febrile Neutropenia

12 (29)

10 (24)

Thrombocytopenia

11 (27)

10 (24)

Anemia

9 (22)

4 (10)

Neutropenia

4 (10)

4 (10)

Leukopenia

4 (10)

1 (2)

Non-Hematologic

Nausea

18 (44)

2 (5)

Constipation

17 (41)

0

Fatigue

17 (41)

4 (10)

Peripheral Edema

6 (15)

0

Vomiting

6 (15)

0

Diarrhea

5 (12)

1 (2)

Dizziness

5 (12)

0

Headache

5 (12)

1 (2)

Hypokalemia

5 (12)

0

Pyrexia

4 (10)

0

Cellulitis

4 (10)

4 (10)

Rash

4 (10)

0

Hypotension

4 (10)

0

Cough

4 (10)

0

Dyspnea

4 (10)

0

QTc Prolongation*

2 (5)

1 (2)

*QTC events were seen in < 10% of patients, however are noted here

18

Treatment Emergent Adverse Events Leading

to Drug Discontinuation

AE Term

Grade

Discontinuation

(Cycle/Day)

Outcome

Peripheral Motor Neuropathy

3

3/1

Resolved

Parainfluenza

3

3/22

Resolved

Prolonged QTc/AF

3

2/15

Resolved

Subdural Hematoma

5

3/22

Fatal

Sepsis

5

2/3

Fatal

Sepsis

5

2/14

Fatal

AE, adverse event; AF, atrial fibrillation.

19

Response

Interim Response Assessment

n=33* (%)

CR/CRi/MLFS (Primary endpoint)

15 (45)

CR

9 (27)

CRi

4 (12)

MLFS

2 (6)

PR/PRi

3 (10)

Stable Disease

4 (12)

Progressive Disease

6 (18)

Clinical Benefit**

1 (3)

No Clinical Benefit

4 (12)

*All

patients

who

have

had

at

least

1

on-study

disease

assessment

OR

discontinued

study

therapy

prior

to

an

on

study

disease

assessment due to adverse event or other reasons

** Patients did not meet strict International Working Group (IWG) response criteria, but were determined to have clinical benefit

by Investigator

20

Evolution of Clinical Responses:

Interim Efficacy and Duration on Study

21

Event Free Survival

22

Overall Survival

23

Bone Marrow Response in MDS and AML

n = 27; 6 patients had no on-study BM performed

MDS Pilot Study

n = 9

Phase II AML Study

200

180

160

140

120

100

80

60

40

20

0

-20

-40

-60

-80

-100

-120

50

40

30

20

10

0

-10

-20

-30

-40

-50

-60

-70

-80

-90

-100

-110

24

Conclusions

•

Pracinostat in combination with azacitidine demonstrates significant

clinical activity in elderly patients with newly diagnosed AML

To date, 15 of 33 patients (45%) achieved the primary endpoint of

CR+CRi+MLFS

No patient who achieved a clinical response has progressed

Most clinical responses occur within the first 2 cycles and continue to

improve with ongoing therapy

The observed Response Rate may increase with longer follow up of

patients achieving PR or SD

The 60 day mortality rate is approximately 10% (3/33)

25

Conclusions (cont’d)

•

Pracinostat in combination with azacitidine was well tolerated in this

population of elderly AML patients

The most common treatment-emergent AEs included neutropenia,

febrile neutropenia, thrombocytopenia, nausea, fatigue and anemia

Adverse events resulting in dose reductions

were uncommon, and

frequently due to disease under study

Six patients to date have received study drug beyond 230 days

reflecting long term tolerability

•

These data support definitive development of Pracinostat in

combination with azacitidine in elderly AML patients

Pracinostat: Looking Ahead

Robert D. Mass, MD

Chief Medical Officer

27

Elderly (Age

60 years) Patients with Newly Diagnosed AML

Unsuitable for Intensive Therapy

Pracinostat

+

Azacitidine

Placebo

+

Azacitidine

Proposed Phase III AML Study Designs

•

Primary endpoint: CR

Secondary endpoints: OS, ORR, transfusion independency rate,

duration of response, PFS, tolerability and AE rate, PK

•

~450 patients, one-to-one randomization

•

Estimated initiation: June 2015

28

Intermediate Risk-2 or High Risk MDS Patients

Previously Untreated w/ HMA

Pracinostat

+

Azacitidine

Placebo

+

Azacitidine

Phase II Front Line MDS Study (MEI-003)

•

Primary Endpoint: CR

Secondary endpoints: overall response rate, hematologic improvement,

clinical benefit rate, duration of response, progression-free survival, rate

of leukemic transformation, overall survival, safety & tolerability

•

102 evaluable patients enrolled, one-to-one randomization

•

24 sites in the U.S.

•

Expect to unblind study and report topline data in March 2015

29

Phase II Front Line MDS Study (MEI-003)

Patient Demographics

Study MEI-003

(N=102)

Pub

(N=99)

Pub

(N=179)

Age

Median

<65

>65

70 yrs

29%

71%

69 yrs

NR

NR

69 yrs

32%

68%

Gender

Male

Female

69%

31%

72%

27%

74%

26%

PS

0

1

2

34%

57%

9%

NR

NR

NR

44%

48%

7%

IPSS

INT-2

High

65%

35%

11%

9%

43%

46%

1

Based on unclean data; study closed to enrollment on August 29, 2014

2

Vidaza

®

package insert, table 1 (Silverman, JCO 2002 study)

3

Vidaza

®

package insert, table 2 (Fenaux, Lancet Oncology 2009 study)

1

2

3

30

2015 Clinical Milestones

Pracinostat

Top line data from Phase II study in front line MDS (March)

Full data set from Phase II study in front line MDS (June)

Initiation of Phase III study in front line elderly AML (June)

ME-344

Data from Phase Ib trial in small cell lung & ovarian cancers

PWT143

Initiation of first-in-human study

[ NASDAQ: MEIP ]

Analyst & Investor Event

December 8, 2014

Q & A